the us studies report higher drug costs for cinv prophylaxis with palonosetron compared with ondansetron, lower medical outpatient and inpatient costs for palonosetron versus other 5-ht3ras, and higher acquisition costs for palonosetron versus ondansetron or other 5-ht3ras.